The goal of this activity is for learners to be better able to assess the safety and efficacy of LAG3 inhibitors for the treatment of melanoma.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 0.25 credits
MOC types
ABIM — Medical KnowledgeUp to 0.25 points
FDA REMS
No
Qualifies for MIPS
No
Target Specialties
Address:
- 283 - 299 Market St.
Pricing
100% of listed courses are free
300 of a sample of 300 are free · 1,252 courses listed here.
Collected from the provider’s public pages
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Breast Imaging
- Cardiovascular Disease
- Clinical Cardiac Electrophysiology
- Clinical Informatics
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Facial Plastic & Reconstructive Surgery
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Hospital Medicine
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Neonatal-Perinatal Medicine
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Nuclear Medicine
- Obstetric Anesthesia
- Obstetrics & Gynecology
- Ophthalmology
- Otology & Neurotology
- Pain Medicine
- Patient Education & Health Literacy
- Patient Safety & Quality Improvement
- Pediatric Gastroenterology
- Pediatric Neurology
- Plastic & Reconstructive Surgery
- Preventive Medicine
- Primary Care Sports Medicine
- Pulmonary Disease
- Rheumatology
- Rhinology
- Sleep Medicine
- Transplant Hepatology
- Urological Oncology
- Vascular Neurology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Sports & Exercise Medicine
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.25 credits
- MOC · Up to 0.25 points
- Commercial Support
-
ReleasedDec 11, 2025
-
Last day to claim creditDec 12, 2026 2 months left
-
Medscape, LLC Clinical Quiz: Patient Eligibility and Clinical Trial Enrollment for LAG3 Inhibitors in Melanoma
-
Medscape, LLC The Spectrum of LAG-3 in Melanoma: A Preview Across Treatment Settings
-
Medscape, LLC Different Perspectives, Parallel Journey: A Clinician-Patient Interview on LAG3 in Melanoma
-
PRIME Education, Inc. (PRIME®) Advancing Immune Checkpoint Inhibitor Use in Resectable Melanoma
-
Learner’s Digest International (TM) Navigating the Complexities of Advanced Melanoma Treatment
-
National Comprehensive Cancer Network The Next Frontier for CDK4/6 Inhibitors in Breast Cancer: Expert Strategies for Applying the Latest Guidelines and Advances in Practice
